Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery

Abstract

The antithrombin binding sequence of heparin, a pentasaccharide, has been synthesized as fondaparinux, an indirect, selective, and reversible factor Xa inhibitor. It can be administered subcutaneously, is well absorbed, and has a half-life of c. 17 hours permitting once-daily injection. It has been evaluated in an extensive study program in major orthopedic surgery, including hip fracture, and in major abdominal surgery with a large proportion of surgery for cancer. The effect is at least as effective as for low-molecular-weight heparins and it has also been shown effective for extended prophylaxis in hip fracture patients. Several thousands of patients have been studied and the substance is safe, although a slightly higher frequency of bleedings is found than in patients on low-molecular-weight heparins. There is no specific antidote but if necessary, recombinant activated factor VII can be used. Other side-effects are rare. Fondaparinux is cost saving and sometimes cost neutral when compared with enoxaparin.

Keywords:

• fondaparinux
• venous thrombosis
• venous thromboembolism
• surgery
• orthopedic surgery
• major abdominal surgery
• bleeding complications

Disclosures

The author belonged to the steering committee of the PEGASUS trial (fondaparinux in high risk abdominal surgery).